PMID- 31377434
OWN - NLM
STAT- MEDLINE
DCOM- 20191127
LR  - 20191127
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 142
DP  - 2019 Oct
TI  - How do skeletal morbidity rate and special toxicities affect 12-week versus 
      4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis 
      of randomized trials.
PG  - 68-75
LID - S1040-8428(19)30148-9 [pii]
LID - 10.1016/j.critrevonc.2019.07.013 [doi]
AB  - BACKGROUND: Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the 
      treatment of bone metastases. Some randomized trials supported its role also when 
      administered every 12 weeks. METHODS: we performed a systematic review and a 
      meta-analysis in order to evaluate the two different schedules in terms of 
      skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events 
      (AEs). RESULTS: our results showed a clinical difference favouring the 12-week 
      schedule in terms of AEs (RR 1.17, 95% CI 1.06-1.29). No signifcant differences 
      were found for SMR (RR 0.97, 95% CI 0.84-1.13) and SRE (RR 1.02, 95% CI 
      0.89-1.16). CONCLUSIONS: Our findings support in clinical practice the 12-week 
      schedule an alternative to the standard 4-week schedule in advanced breast and 
      prostate cancer, in particular when the clinical comorbidities of the patients 
      suggest a higher risk of renal failure or hypocalcaemia.
CI  - Copyright (c) 2019. Published by Elsevier B.V.
FAU - Santini, Daniele
AU  - Santini D
AD  - Medical Oncology, Campus Biomedico University, Roma, Italy.
FAU - Galvano, Antonio
AU  - Galvano A
AD  - Medical Oncology, Department of Surgical, Oncological and Stomatological 
      Sciences, University of Palermo, Palermo, Italy.
FAU - Pantano, Francesco
AU  - Pantano F
AD  - Medical Oncology, Campus Biomedico University, Roma, Italy.
FAU - Incorvaia, Lorena
AU  - Incorvaia L
AD  - Medical Oncology, Department of Surgical, Oncological and Stomatological 
      Sciences, University of Palermo, Palermo, Italy.
FAU - Rizzo, Sergio
AU  - Rizzo S
AD  - Medical Oncology, Department of Surgical, Oncological and Stomatological 
      Sciences, University of Palermo, Palermo, Italy.
FAU - Vincenzi, Bruno
AU  - Vincenzi B
AD  - Medical Oncology, Campus Biomedico University, Roma, Italy.
FAU - Castellana, Luisa
AU  - Castellana L
AD  - Medical Oncology, Department of Surgical, Oncological and Stomatological 
      Sciences, University of Palermo, Palermo, Italy.
FAU - Giuliana, Giovanna
AU  - Giuliana G
AD  - Medical Oncology, Department of Surgical, Oncological and Stomatological 
      Sciences, University of Palermo, Palermo, Italy.
FAU - Guadagni, Fiorella
AU  - Guadagni F
AD  - Department of Human Sciences and Quality of Life Promotion, San Raffaele Roma 
      Open University, Rome 00166, Italy; InterInstitutional Multidisciplinary Biobank, 
      IRCCS San Raffaele Pisana, Rome, Italy.
FAU - Toia, Francesca
AU  - Toia F
AD  - Plastic and Reconstructive Surgery Section, Department of Surgical, Oncological 
      and Stomatological Sciences, University of Palermo, Palermo, Italy.
FAU - Tonini, Giuseppe
AU  - Tonini G
AD  - Medical Oncology, Campus Biomedico University, Roma, Italy.
FAU - Russo, Antonio
AU  - Russo A
AD  - Medical Oncology, Department of Surgical, Oncological and Stomatological 
      Sciences, University of Palermo, Palermo, Italy. Electronic address: 
      antonio.russo@usa.net.
FAU - Badalamenti, Giuseppe
AU  - Badalamenti G
AD  - Medical Oncology, Department of Surgical, Oncological and Stomatological 
      Sciences, University of Palermo, Palermo, Italy.
FAU - Bazan, Viviana
AU  - Bazan V
AD  - Medical Oncology, Department of Surgical, Oncological and Stomatological 
      Sciences, University of Palermo, Palermo, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190725
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Bone Density Conservation Agents)
RN  - 6XC1PAD3KF (Zoledronic Acid)
SB  - IM
MH  - Bone Density Conservation Agents/adverse effects/therapeutic use
MH  - Bone Neoplasms/*drug therapy/secondary
MH  - Breast Neoplasms/pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/pathology
MH  - Treatment Outcome
MH  - Zoledronic Acid/administration & dosage/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - AEs
OT  - Bone metastases
OT  - Breast
OT  - Meta-Analysis
OT  - Prostate
OT  - SMR
OT  - Solid tumors
OT  - Zoledronic acid
EDAT- 2019/08/05 06:00
MHDA- 2019/11/28 06:00
CRDT- 2019/08/05 06:00
PHST- 2019/05/02 00:00 [received]
PHST- 2019/07/16 00:00 [revised]
PHST- 2019/07/16 00:00 [accepted]
PHST- 2019/08/05 06:00 [pubmed]
PHST- 2019/11/28 06:00 [medline]
PHST- 2019/08/05 06:00 [entrez]
AID - S1040-8428(19)30148-9 [pii]
AID - 10.1016/j.critrevonc.2019.07.013 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2019 Oct;142:68-75. doi: 
      10.1016/j.critrevonc.2019.07.013. Epub 2019 Jul 25.